INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒══════════════════════════════════╤═════════════════════════════════╤═════════╕
│ Personal Criteria                │ CHIA Criteria                   │   Score │
╞══════════════════════════════════╪═════════════════════════════════╪═════════╡
│ Healthy adults 30 - 70 years old │ Healthy adults 30- 65 years old │      92 │
╘══════════════════════════════════╧═════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Pregnant or lactating                              │ Less than 30 yrs of age or > 65 yrs of age         │      29 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women unwilling to use an effective birth control  │ nondiabetic as defined by fasting plasma glucose   │      35 │
│ method                                             │ <126 mg/dL                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of statin intolerance                      │ Less than 30 yrs of age or > 65 yrs of age         │      37 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Individuals taking any medications for weight loss │ Any significant co-morbidities, such as active     │      38 │
│ or known to influence insulin sensitivity          │ heart, kidney, or liver diseases, accelerated or   │         │
│                                                    │ malignant hypertension, heart failure, severe      │         │
│                                                    │ anemia                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eligible for statin therapy for primary prevention │ Lipids: one group with an LDL =/>130 and           │      40 │
│ of ASCVD based on LDL-C ≥ 130 mg/dL, \> 5% ASCVD   │ Triglycerides < 150 mg/dL The 2nd group will have  │         │
│ risk over 10 years, or hs-CRP ≥ 2.0 mg/L           │ and LDL=/>130 mg/dL and Triglycerides =/>150 mg/dL │         │
│                                                    │ but less than 400 mg/dL                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 30 Years                  │ Less than 30 yrs of age or > 65 yrs of age         │      40 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 70 Years                  │ Less than 30 yrs of age or > 65 yrs of age         │      40 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persons with any significant co-morbidities, such  │ Any significant co-morbidities, such as active     │      51 │
│ as diabetes (fasting glucose ≥ 126 mg/dL or use of │ heart, kidney, or liver diseases, accelerated or   │         │
│ glucose lowering medications), active coronary     │ malignant hypertension, heart failure, severe      │         │
│ artery disease, heart failure, accelerated or      │ anemia                                             │         │
│ malignant hypertension, kidney disease (creatinine │                                                    │         │
│ ≥ 1.5 mg/dL), liver disease (alanine               │                                                    │         │
│ aminotransferase \> 2 times upper limit of         │                                                    │         │
│ normal), or severe anemia (hematocrit \< 30%)      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Younger than 30 or older than 70 years             │ Less than 30 yrs of age or > 65 yrs of age         │      52 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Without diabetes as defined by fasting plasma      │ nondiabetic as defined by fasting plasma glucose   │      65 │
│ glucose \<126 mg/dL and not taking glucose         │ <126 mg/dL                                         │         │
│ lowering medications                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ BMI: 20 - 37 kg/m2                                 │ BMI 25-35 kg/m2                                    │      79 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Eligible for statin therapy for primary prevention │ Lipids: one group with an LDL =/>130 and           │      40 │
│ of ASCVD based on LDL-C ≥ 130 mg/dL, \> 5% ASCVD   │ Triglycerides < 150 mg/dL The 2nd group will have  │         │
│ risk over 10 years, or hs-CRP ≥ 2.0 mg/L           │ and LDL=/>130 mg/dL and Triglycerides =/>150 mg/dL │         │
│                                                    │ but less than 400 mg/dL                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persons with any significant co-morbidities, such  │ Any significant co-morbidities, such as active     │      51 │
│ as diabetes (fasting glucose ≥ 126 mg/dL or use of │ heart, kidney, or liver diseases, accelerated or   │         │
│ glucose lowering medications), active coronary     │ malignant hypertension, heart failure, severe      │         │
│ artery disease, heart failure, accelerated or      │ anemia                                             │         │
│ malignant hypertension, kidney disease (creatinine │                                                    │         │
│ ≥ 1.5 mg/dL), liver disease (alanine               │                                                    │         │
│ aminotransferase \> 2 times upper limit of         │                                                    │         │
│ normal), or severe anemia (hematocrit \< 30%)      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Younger than 30 or older than 70 years             │ Less than 30 yrs of age or > 65 yrs of age         │      52 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Without diabetes as defined by fasting plasma      │ nondiabetic as defined by fasting plasma glucose   │      65 │
│ glucose \<126 mg/dL and not taking glucose         │ <126 mg/dL                                         │         │
│ lowering medications                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ BMI: 20 - 37 kg/m2                                 │ BMI 25-35 kg/m2                                    │      79 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 46
Average Levenshtein Ratio of individual lines: 52.05882352941177
OverAll Ratio: 49.029411764705884
